Carregant...
A personalized approach to acute myeloid leukemia therapy: current options
Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic land...
Guardat en:
| Publicat a: | Pharmgenomics Pers Med |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6684879/ https://ncbi.nlm.nih.gov/pubmed/31447578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S168267 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|